Daniel M. Geynisman, MD, on the real-world analysis of abiraterone acetate & docetaxel in mHSPC

Edwin M. Posadas, MD, and Robert A. Figlin, MD discuss how data from the recent EMBARK trial have changed prostate cancer practice and introduced “a whole new challenge.”

Olaparib and abiraterone are more effective than either agent alone or sequentially in previously untreated metastatic castration-resistant prostate cancer.

Elizabeth Guancial, MD, discusses how the recent chemotherapy drug shortage affected bladder cancer care and what may help with such situations in the future.

Adjuvant pembrolizumab improved survival in high-risk renal cell cancer, but adjuvant ipilimumab did not, leaving experts debating the differences.

Adjuvant pembrolizumab after cystectomy improves disease-free survival for patients with muscle-invasive urothelial carcinoma, new data show.

Long-term ADT with dose-escalated radiotherapy safely improves survival in high-risk prostate cancer compared with conventional-dose radiation therapy.

Findings from clinical trials evaluating immunotherapy in bladder and kidney cancers will take center stage at the 2024 ASCO Genitourinary Cancers Symposium.

Daniel Petrylak, MD, discusses advances and challenges in bladder cancer, including including the bacillus Calmette-Guérin (BCG) shortage.

Mark Tyson, II, MD, MPH, highlights key urothelial carcinoma trials at ASCO GU and how new agents may reduce the need for cystectomy in early bladder cancer.

Sumanta Pal, MD, discusses key bladder cancer data presented at the meeting, including adjuvant nivolumab in high-risk disease.

Urinary tumor DNA may be a viable marker for non-muscle invasive bladder cancer, according to a new feasibility study.

Immunotherapy and intensive brain-directed therapies are independently tied to longer survival in patients with renal cell carcinoma and brain metastases.